Drug Trial Radar · NCT07025018
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations
Conditions
- Gliomas Harboring IDH1 and/or IDH2 Mutations
Interventions
HMPL-306Drug
IDH small molecule inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days after first dose of study drug
- RP2DTime frame: From first dose of study drug to the time of progressive disease, assessed up to 24 months on average
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.